ALDX Aldeyra Therapeutics Inc
Price (delayed)
$6.69
Market cap
$398.39M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.75
Enterprise value
$345.88M
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's
Highlights
The quick ratio has soared by 51% since the previous quarter
Aldeyra Therapeutics's debt has decreased by 3.5% YoY
The company's EPS fell by 17% QoQ but it rose by 3.8% YoY
ALDX's equity is down by 31% year-on-year and by 13% since the previous quarter
The net income has contracted by 18% from the previous quarter
Key stats
What are the main financial stats of ALDX
Market
Valuations
Earnings
Shares outstanding
59.55M
Market cap
$398.39M
Enterprise value
$345.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$49.64M
Net income
-$44.8M
EBIT
-$42.83M
EBITDA
-$42.57M
Free cash flow
-$30.67M
Per share
Balance sheet
Liquidity
EPS
-$0.75
EPS diluted
-$0.75
Free cash flow per share
-$0.52
Book value per share
$1.43
Revenue per share
$0
TBVPS
$1.97
Total assets
$117.32M
Total liabilities
$32.22M
Debt
$15.61M
Equity
$85.1M
Working capital
$99.57M
Debt to equity
0.18
Current ratio
6.8
Quick ratio
6.57
Net debt/EBITDA
1.23
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.6%
Return on equity
-43%
Return on invested capital
-139.9%
Return on capital employed
-42.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALDX stock price
How has the Aldeyra Therapeutics stock price performed over time
Intraday
-0.45%
1 week
3.08%
1 month
36.81%
1 year
99.7%
YTD
34.07%
QTD
34.07%
Financial performance
How have Aldeyra Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$49.64M
Net income
-$44.8M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 18% from the previous quarter
Aldeyra Therapeutics's operating income has decreased by 15% QoQ
Growth
What is Aldeyra Therapeutics's growth rate over time
Valuation
What is Aldeyra Therapeutics stock price valuation
P/E
N/A
P/B
4.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 17% QoQ but it rose by 3.8% YoY
ALDX's price to book (P/B) is 103% more than its last 4 quarters average of 2.3 and 73% more than its 5-year quarterly average of 2.7
ALDX's equity is down by 31% year-on-year and by 13% since the previous quarter
Efficiency
How efficient is Aldeyra Therapeutics business performance
The return on invested capital has surged by 65% year-on-year and by 29% since the previous quarter
The ROE has contracted by 29% from the previous quarter and by 27% YoY
The return on assets has declined by 25% since the previous quarter and by 20% year-on-year
Dividends
What is ALDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALDX.
Financial health
How did Aldeyra Therapeutics financials performed over time
The quick ratio has soared by 51% since the previous quarter
The current ratio is up by 49% since the previous quarter
Aldeyra Therapeutics's debt is 82% lower than its equity
The company's debt to equity rose by 38% YoY and by 13% QoQ
ALDX's equity is down by 31% year-on-year and by 13% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.